Source: International Congress 2014 – ILDs 2
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
X. He, X. Long, T. E. Wessendorf, D. Theegarten, J. Guzman, U. Costabel, F. Bonella (Essen, Bochum, Germany). Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP). Eur Respir J 2014; 44: Suppl. 58, 764

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 A mechanism for acceleration of GM-CSF autoantibody (GMAb) production in autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2014 – Molecular pathogenesis of pulmonary inflammatory diseases (COPD, asthma and ILD) Year: 2014 MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Lipoxin (LXA4) as a novel therapy for idiopathic pulmonary fibrosis Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Imbalance of M1/M2 alveolar macrophages phenotype in pulmonary sarcodosis Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 A potential role for endothelial adhesion molecules and cytokines in chemotherapy-induced lung fibrosis Source: International Congress 2014 – Cell biology 2014 Year: 2014 Mucus production, lung inflammation and functional decay in IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Functional phenotype of immune response and alveolar macrophages phenotype in pulmonary sarcoidosis Source: International Congress 2014 – New insights into monocyte and macrophage biology Year: 2014 Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Increased apoptosis of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF). Potential mechanisms and practical considerations Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Specific activation of non-classical Th1 cells in pulmonary sarcoidosis Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014